Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emb-01
- Development stage
- Phase 2
- Lead developer
- EpimAb Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
EMB-01 (also known as bafisontamab) is a novel bispecific monoclonal antibody developed using EpimAb’s proprietary FIT-Ig platform. It simultaneously targets the Epidermal Growth Factor Receptor (EGFR) and c-Mesenchymal-Epithelial Transition factor (cMet) on tumor cells. By binding to both EGFR and cMet, EMB-01 is designed to inhibit signaling pathways that drive tumor growth and resistance mechanisms in various cancers. The drug is being investigated primarily for advanced/metastatic solid tumors, including non-small cell lung cancer (NSCLC) with EGFR mutations or cMET aberrations, as well as several gastrointestinal cancers such as gastric cancer, hepatocellular carcinoma, cholangiocarcinoma, and colorectal cancer[5][6][10]. Clinical trials are ongoing in the US and China.
- Brand names
- bafisontamab
- Other names
- anti-egfr/anti-c-met bispecific antibody emb-01anti-egfr/c-met bispecific antibody emb-01
02
Targets
EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on emb-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emb-01.